vs
诺唯真游轮控股（LINE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
诺唯真游轮控股的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs -7.3%，领先20.0%），Revvity同比增速更快（5.9% vs 3.1%），Revvity自由现金流更多（$161.8M vs $35.0M）
诺唯真游轮控股是一家总部位于美国、注册地为百慕大的企业，旗下全资运营诺唯真游轮、大洋游轮、丽晶七海游轮三大品牌，合并业务规模位列全球游轮运营商第三位，目前在纽约证券交易所挂牌上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LINE vs RVTY — 直观对比
营收规模更大
LINE
是对方的1.8倍
$772.1M
营收增速更快
RVTY
高出2.7%
3.1%
净利率更高
RVTY
高出20.0%
-7.3%
自由现金流更多
RVTY
多$126.8M
$35.0M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $-100.0M | $98.4M |
| 毛利率 | 32.3% | — |
| 营业利润率 | 2.5% | 14.5% |
| 净利率 | -7.3% | 12.7% |
| 营收同比 | 3.1% | 5.9% |
| 净利润同比 | 79.4% | 3.9% |
| 每股收益（稀释后） | $-0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LINERVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润LINERVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-100.0M | $46.7M | ||
| Q2 25 | $-6.0M | $53.9M | ||
| Q1 25 | $0 | $42.2M | ||
| Q4 24 | $-71.0M | $94.6M | ||
| Q3 24 | $-485.0M | $94.4M | ||
| Q2 24 | $-68.0M | $55.4M | ||
| Q1 24 | $-40.0M | $26.0M |
毛利率LINERVTY
| Q4 25 | — | — | ||
| Q3 25 | 32.3% | 53.6% | ||
| Q2 25 | 31.9% | 54.5% | ||
| Q1 25 | 32.2% | 56.5% | ||
| Q4 24 | 32.3% | — | ||
| Q3 24 | 32.8% | 56.3% | ||
| Q2 24 | 33.4% | 55.7% | ||
| Q1 24 | 33.4% | 54.6% |
营业利润率LINERVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 2.5% | 11.7% | ||
| Q2 25 | 1.7% | 12.6% | ||
| Q1 25 | 4.3% | 10.9% | ||
| Q4 24 | -1.6% | 16.3% | ||
| Q3 24 | -38.6% | 14.3% | ||
| Q2 24 | 5.5% | 12.4% | ||
| Q1 24 | 7.6% | 6.8% |
净利率LINERVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -7.3% | 6.7% | ||
| Q2 25 | -0.4% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | -5.3% | 13.0% | ||
| Q3 24 | -36.3% | 13.8% | ||
| Q2 24 | -5.1% | 8.0% | ||
| Q1 24 | -3.0% | 4.0% |
每股收益（稀释后）LINERVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $-0.44 | $0.40 | ||
| Q2 25 | $-0.03 | $0.46 | ||
| Q1 25 | $0.01 | $0.35 | ||
| Q4 24 | $-0.52 | $0.77 | ||
| Q3 24 | $-2.44 | $0.77 | ||
| Q2 24 | $-0.46 | $0.45 | ||
| Q1 24 | $-0.28 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.4B | $7.3B |
| 总资产 | $19.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LINERVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $173.0M | $1.2B | ||
| Q3 24 | $409.0M | $1.2B | ||
| Q2 24 | $73.0M | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益LINERVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $8.4B | $7.4B | ||
| Q2 25 | $8.6B | $7.6B | ||
| Q1 25 | $8.6B | $7.6B | ||
| Q4 24 | $8.6B | $7.7B | ||
| Q3 24 | $9.0B | $7.9B | ||
| Q2 24 | $4.9B | $7.9B | ||
| Q1 24 | $5.6B | $7.8B |
总资产LINERVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $19.2B | $12.1B | ||
| Q2 25 | $19.4B | $12.4B | ||
| Q1 25 | $18.8B | $12.4B | ||
| Q4 24 | $18.7B | $12.4B | ||
| Q3 24 | $19.3B | $12.8B | ||
| Q2 24 | $18.8B | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $230.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $35.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 2.5% | 21.0% |
| 资本支出强度资本支出/营收 | 14.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流LINERVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $230.0M | $138.5M | ||
| Q2 25 | $258.0M | $134.3M | ||
| Q1 25 | $139.0M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $186.0M | $147.9M | ||
| Q2 24 | $155.0M | $158.6M | ||
| Q1 24 | $105.0M | $147.6M |
自由现金流LINERVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $35.0M | $120.0M | ||
| Q2 25 | $95.0M | $115.5M | ||
| Q1 25 | $-12.0M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $33.0M | $125.6M | ||
| Q2 24 | $-31.0M | $136.6M | ||
| Q1 24 | $-42.0M | $129.7M |
自由现金流率LINERVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 2.5% | 17.2% | ||
| Q2 25 | 7.0% | 16.0% | ||
| Q1 25 | -0.9% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 2.5% | 18.4% | ||
| Q2 24 | -2.3% | 19.7% | ||
| Q1 24 | -3.2% | 20.0% |
资本支出强度LINERVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 14.2% | 2.6% | ||
| Q2 25 | 12.1% | 2.6% | ||
| Q1 25 | 11.7% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 11.5% | 3.3% | ||
| Q2 24 | 13.9% | 3.2% | ||
| Q1 24 | 11.1% | 2.7% |
现金转化率LINERVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LINE
| Warehousing Operations | $883.0M | 64% |
| Other | $308.0M | 22% |
| Warehouse Lease | $60.0M | 4% |
| Food Sales | $52.0M | 4% |
| E Commerce And Other | $46.0M | 3% |
| Railcar Lease | $23.0M | 2% |
| Service Other | $5.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
